COSM

Cosmos Health Inc. (COSM) - 10-K Summary for Fiscal Year Ended December 31, 2025

Business Context and Reporting Period

Cosmos Health Inc. is a vertically integrated global healthcare group incorporated in Nevada, with principal executive offices in Thessaloniki, Greece. The company operates in the pharmaceutical and nutraceutical sectors, offering generic medicines, proprietary nutraceutical brands (Sky Premium Life, Mediterranation), biocides, and telehealth services. The company also engages in R&D for innovative medicines and drug repurposing via its AI platform, Cloudscreen. This report covers the fiscal year ended December 31, 2025.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 19.9% to $65.3M, driven by a 15% increase in wholesale revenues (Cosmofarm S.A.), a near-doubling of pharmaceutical manufacturing revenues (CANA S.A.), and significant growth in the UK subsidiary (Decahedron Ltd.).
• Margin Expansion: Gross margin improved to 12.1% from 7.9% due to a favorable shift in revenue mix toward higher-margin manufacturing and branded nutraceutical segments.
• Increased Loss: Net loss widened by 18.3% to $19.1M. This was primarily driven by a $5.9M provision for doubtful accounts (including a $3.9M full allowance against a related-party loan to Doc Pharma S.A.), increased stock-based compensation ($2.3M), and higher management bonuses.
• Digital Asset Strategy: The company invested $2.0M in Ethereum (ETH) during 2025, resulting in an unrealized loss of $588,916 recorded in the period.
• Debt Structure: The company significantly increased leverage, issuing approximately $9.8M in convertible notes and utilizing an At-the-Market (ATM) equity program to raise $5.4M in gross proceeds.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative operating cash flows. The company relies on continued access to capital markets (ATM program, convertible notes) and the execution of new distribution agreements (e.g., UAE) to sustain operations.
• Unusual Items:
  • Related Party Allowance: A $3.9M non-cash charge was recorded against a loan receivable from Doc Pharma S.A. due to 18 months of non-payment.
  • Debt Extinguishment: A $68,610 gain was recognized from converting a promissory note related to the Cloudscreen acquisition into equity.
  • Derivative Gains/Losses: The company recorded a $1.5M gain on the change in fair value of derivative liabilities but a $1.3M loss on the change in fair value of convertible notes.
• Risks: Key risks include dependence on capital markets, currency exchange fluctuations (97% of revenue is non-USD), regulatory changes in the EU and US (Inflation Reduction Act), and the collectability of significant receivables from related parties and distributors (Medihelm S.A.).
• Outlook: The company plans to expand its product portfolio, pursue vertical integration, and leverage its AI drug repurposing platform. It expects to commence initial US operations in 2026.

Investor Verification Checklist

• Going Concern Status: Verify the company's ability to secure additional financing given the substantial doubt expressed by management and the auditor.
• Related Party Receivables: Assess the recoverability of the $3.3M receivable from Doc Pharma S.A. and the $1.7M allowance already recorded, as well as the $1.7M receivable from Medihelm S.A.
• Digital Asset Exposure: Review the valuation and liquidity of the $1.4M Ethereum holding and the strategy behind allocating restricted cash to crypto assets.
• Debt Covenants: Confirm compliance with financial covenants on the new $8M convertible note facility and other lines of credit.
• Revenue Quality: Analyze the concentration of revenue in Greece (97.3%) and the sustainability of growth in the wholesale segment versus higher-margin segments.